Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1918
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice ; day:1 ; month:9 ; year:2016 ; pages:1-10
Clinical drug investigation ; (1.9.2016), 1-10
- Urheber
-
Lackey, Philip
- Beteiligte Personen und Organisationen
-
Mills, Anthony
Carpio, Felix
Hsu, Ricky
DeJesus, Edwin
Pierone, Gerald
Henegar, Cassidy
Fusco, Jennifer
Fusco, Gregory
Wohlfeiler, Mike
SpringerLink (Online service)
- DOI
-
10.1007/s40261-016-0456-1
- URN
-
urn:nbn:de:1111-201609295658
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lackey, Philip
- Mills, Anthony
- Carpio, Felix
- Hsu, Ricky
- DeJesus, Edwin
- Pierone, Gerald
- Henegar, Cassidy
- Fusco, Jennifer
- Fusco, Gregory
- Wohlfeiler, Mike
- SpringerLink (Online service)
Ähnliche Objekte (12)
Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption
Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption
Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatments
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children